{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:32:18Z","timestamp":1740130338780,"version":"3.37.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"JSPS KAKENHI","award":["JP18K09297"],"award-info":[{"award-number":["JP18K09297"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>this prospective cohort study aimed to assess the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>in this study, 40 Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer selected to receive bevacizumab with chemotherapy were enrolled. Patients in poor general condition were excluded. Each patient was monitored prospectively for adverse events, administration status, disease status and survival. Treatment was continued until intolerable adverse events or disease progression. The primary endpoint was safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>bevacizumab plus platinum-based chemotherapy was performed for 30 patients (median cycle; 16.5), while bevacizumab plus non-platinum chemotherapy was performed for 10 patients (median cycle; 5.5). Among bevacizumab-related adverse events, hypertension occurred in 80% of patients, proteinuria in 83%, mucositis in 25%, bleeding in 20%, thromboembolic events in 5.0% and fistula in 2.5%. Gastrointestinal perforation or other life-threatening lethal adverse events were not observed. Response rate and median progression-free survival were 73% and 19.3\u00a0months for patients with bevacizumab plus platinum-based chemotherapy, and 30% and 3.9\u00a0months for patients with bevacizumab plus non-platinum chemotherapy, respectively. There was no correlation between response rate and occurrence of adverse events such as hypertension or proteinuria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>bevacizumab combined with chemotherapy was tolerable and effective for Japanese patients with relapsed ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Hypertension and proteinuria are frequently occurred and managed properly for continuing treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa140","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:26:12Z","timestamp":1595503572000},"page":"54-59","source":"Crossref","is-referenced-by-count":2,"title":["A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4039-7212","authenticated-orcid":false,"given":"Yoshiko","family":"Nanki","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"},{"name":"Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, National Hospital Organization Saitama National Hospital, Wako City, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Saotome","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Dozen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yoshihama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa City, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuyuki","family":"Chiyoda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-8326","authenticated-orcid":false,"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"2020122723595467200_ref1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/cas.12525","article-title":"Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data","volume":"105","author":"Ito","year":"2014","journal-title":"Cancer Sci"},{"key":"2020122723595467200_ref2","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"2020122723595467200_ref3","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020122723595467200_ref4","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020122723595467200_ref5","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"2020122723595467200_ref6","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"2020122723595467200_ref7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020122723595467200_ref8","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020122723595467200_ref9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","article-title":"Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective study of safety and efficacy in Japanese patients (JGOG3022 trial)","volume":"24","author":"Komiyama","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2020122723595467200_ref10","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study","volume":"32","author":"Burger","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020122723595467200_ref11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.11.017","article-title":"Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma","volume":"116","author":"Diaz","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2020122723595467200_ref12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","article-title":"Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?","volume":"118","author":"Richardson","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2020122723595467200_ref13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2020122723595467200_ref14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2020122723595467200_ref15","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1097\/MD.0000000000000975","article-title":"Specific safety profile of Bevacizumab in Asian patients with advanced NSCLC: a meta-analysis","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2020122723595467200_ref16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00280-012-2028-2","article-title":"Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer","volume":"71","author":"Morita","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020122723595467200_ref17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IGC.0000000000000836","article-title":"Efficacy and safety of Bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA single-arm phase 3B study","volume":"27","author":"Oza","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"2020122723595467200_ref18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"2020122723595467200_ref19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MCG.0b013e3182a8804c","article-title":"Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer","volume":"48","author":"Khoja","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"2020122723595467200_ref20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12032-012-0327-4","article-title":"Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients","volume":"30","author":"Tahover","year":"2013","journal-title":"Med Oncol"},{"key":"2020122723595467200_ref21","doi-asserted-by":"crossref","first-page":"e000045","DOI":"10.1136\/esmoopen-2016-000045","article-title":"Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer","volume":"1","author":"Dion\u00edsio de Sousa","year":"2016","journal-title":"ESMO Open"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/1\/54\/35142072\/hyaa140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/1\/54\/35142072\/hyaa140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T05:00:19Z","timestamp":1609131619000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/1\/54\/5885448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,8]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa140","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,8,8]]}}}